As emerging biotech and small pharma companies progress through clinical development, pharmacovigilance inevitably becomes a growing priority. Regulatory obligations increase, safety oversight becomes more critical, and organizations must demonstrate that they can manage safety activities in a compliant and inspection-ready manner.

The challenge is not whether PV infrastructure is necessary. It is.

The challenge is knowing how much infrastructure is needed today versus what may be needed years from now.

Many early-stage pharma companies  make the mistake of implementing pharmacovigilance systems and operating models designed for much larger organizations. In an effort to prepare for future growth, they invest in complex platforms, extensive integrations, and enterprise-grade processes long before their business requires them.

The result is often an overbuilt PV environment that creates unnecessary cost, complexity, and operational burden at precisely the stage when agility matters most.

Early-stage pharma companies operate in a fundamentally different environment than commercial pharmaceutical organizations.

Teams are lean. Processes are still evolving. Clinical programs change direction. Funding priorities shift. Organizational structures are often built in parallel with product development activities.

In this environment, committing to a large-scale PV infrastructure too early can create friction rather than efficiency.

Many enterprise pharmacovigilance platforms assume:

• Mature safety operations
• Dedicated internal PV teams
• Established case-processing workflows
• Significant validation and governance resources
• Stable organizational structures

Most early-stage pharma have none of these.

Instead, they are often working with small cross-functional teams and outsourced partners while building foundational compliance capabilities. The infrastructure they need should support this reality,  not assume they have already reached operational maturity.

One of the most common misconceptions in the industry is that regulatory readiness requires enterprise-level systems.

It does not.

Health authorities expect companies to maintain appropriate oversight of safety activities, document their processes, demonstrate compliance, and remain inspection-ready. They do not require organizations to implement the most complex technology available.

In fact, smaller companies can often achieve compliance more effectively through focused, streamlined processes than through large systems that exceed their immediate needs.

The objective should be to establish a pharmacovigilance framework that is proportionate to the organization’s current stage while maintaining the ability to evolve as requirements become more sophisticated.

The financial investment associated with enterprise PV platforms is often only part of the story.

Beyond licensing costs, organizations frequently encounter:

• Lengthy implementation projects
• Extensive validation activities
• Consulting and professional services fees
• Internal training requirements
• Ongoing administration and maintenance efforts

For resource-constrained biotech and emerging pharma companies, these investments can consume valuable time and capital that could otherwise be directed toward clinical development and operational growth.

More importantly, long implementation cycles delay value. While systems are being configured and deployed, regulatory obligations remain unchanged.

Organizations may spend months preparing for a future-state operating model while immediate compliance needs continue to demand attention.

Emerging biotech and small size organizations growth rarely follows a predictable path.

A financing event, licensing agreement, new clinical study, or regulatory milestone can significantly alter operational requirements in a short period of time.

This unpredictability makes flexibility more valuable than feature depth.

The most effective PV infrastructure for early-stage companies is not necessarily the platform with the largest functionality footprint. It is the solution that can adapt as the organization evolves.

That means:

• Supporting outsourced and hybrid operating models
• Allowing processes to mature over time
• Scaling alongside increasing case volumes
• Accommodating organizational growth without requiring major reimplementation

The goal is not to avoid growth. The goal is to avoid paying for complexity before it creates value.

Rather than pursuing enterprise-scale pharmacovigilance environments, early-stage organizations should focus on building a strong operational foundation.

That foundation typically includes:

Clear Safety Processes

Well-defined procedures for case intake, assessment, reporting, and oversight.

Inspection Readiness

Documented responsibilities, governance structures, and evidence of compliance activities.

Efficient Technology

Systems that support operational execution without creating unnecessary administrative burden.

Flexible Service Models

The ability to leverage outsourced expertise while maintaining appropriate sponsor oversight.

Scalable Architecture

Infrastructure that can grow as clinical programs, products, and regulatory obligations expand.

These capabilities provide the rigor required by regulators while preserving the agility needed by emerging companies.

PACE (Progressive Adoption and Cloud Evolution) provides the right-sized approach to PV

Nextrove PACE aligns with the emerging and small pharma organizations current needs while creating a practical path for future growth.

Nextrove PACE allows companies to:

• Achieve compliance quickly
• Maintain inspection readiness
• Minimize operational burden
• Control costs
• Scale efficiently as the business evolves

Most importantly, it enables organizations to focus resources on advancing their products rather than managing unnecessary system complexity.